Buy Actigall

Actigall

What is Actigall?

Actigall is a prescription pill that contains the active ingredient ursodeoxycholic acid (UDCA). UDCA belongs to the class of bile-acid therapies and is used for liver and gallbladder care. In the United Kingdom, Actigall is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) and is only available with a prescription. The medication is supplied as 300 mg oral tablets.

Mechanism of Action

Ursodeoxycholic acid is a naturally occurring, hydrophilic bile acid. It works by several mechanisms that protect the biliary system:

• Reduces cholesterol supersaturation in bile, making cholesterol less likely to precipitate and form stones.
• Improves bile flow by stimulating secretion of bicarbonate-rich bile from cholangiocytes, which helps clear small bile ducts.
• Cytoprotective effect on liver cells, reducing inflammation and slowing the progression of cholestatic liver diseases.
• The drug is absorbed in the small intestine, reaches the liver via the portal circulation, and is reconjugated before being secreted into bile.

These actions explain why UDCA is effective for both gallstone dissolution and certain chronic liver disorders.

Approved Medical Uses

In the UK, Actigall is approved for the following indications:

• Primary biliary cholangitis (PBC) - a chronic autoimmune disease that damages the small bile ducts. UDCA slows disease progression, improves liver-function test results, and can delay the need for liver transplantation.
• Dissolution of cholesterol gallstones - for patients who have small, radiolucent stones and are unsuitable for surgical removal. Treatment aims to gradually dissolve the stones and prevent new stone formation.

Both indications rely on UDCA’s ability to alter bile composition and protect bile-duct cells.

Off-Label and Investigational Applications

Evidence from clinical studies suggests additional potential uses, but these are not approved by the MHRA:

• Intra-hepatic cholestasis of pregnancy (ICP) - Small trials have shown UDCA can improve maternal itch and reduce fetal bilirubin levels. Use in pregnancy remains off-label and should only be considered under specialist supervision.
• Cystic fibrosis-related liver disease - Preliminary data indicate possible benefits in slowing liver fibrosis, though robust trials are lacking.

Off-label use of Actigall requires medical supervision and individualized risk assessment.

Patient Suitability and Contraindications

Who Should Consider Actigall?

• Adults diagnosed with primary biliary cholangitis who have abnormal liver-function tests.
• Patients with cholesterol gallstones who are not candidates for surgery and have stones that are small enough to respond to medical dissolution.

Absolute Contraindications

• Known hypersensitivity to ursodeoxycholic acid or any of the tablet’s inactive ingredients.
• Complete biliary obstruction (e.g., a blocked common bile duct) - the drug cannot be excreted into bile in this situation.
• Pregnancy outside specialist-guided use for ICP (see Off-label section).

Relative Contraindications

• Severe hepatic impairment - while dose adjustment is not standard, careful monitoring is advised.
• Renal impairment - no specific dose change is required, but clinicians may monitor renal function in advanced disease.
• Concurrent use of medications that significantly alter bile-acid metabolism (e.g., strong CYP3A4 inducers) may reduce efficacy.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Mild gastrointestinal upset (nausea, abdominal discomfort) - reported in more than 1 % of users.
• Diarrhoea, usually transient and improves with continued therapy.
• Rarely, headache or mild skin rash.

Serious Adverse Events

• Cholestatic hepatitis - presents with jaundice, itching, and markedly elevated liver enzymes; requires immediate medical attention.
• Severe cutaneous reactions (e.g., Stevens-Johnson syndrome) - extremely rare but possible.
• Liver decompensation in patients with advanced cirrhosis; regular monitoring mitigates risk.

Drug Interactions

• Cyclosporine - UDCA can increase cyclosporine blood levels; dose adjustment and therapeutic-drug monitoring are recommended.
• Anticoagulants (e.g., warfarin) - UDCA may enhance anticoagulant effects; INR should be checked more frequently when therapy begins.
• Other bile-acid agents - concurrent use may lead to additive effects on bile composition; clinicians usually avoid combining them.

Food and Lifestyle Interactions

• Take with meals - food, especially a moderate-fat meal, improves absorption of UDCA.
• Alcohol - moderate consumption is generally acceptable, but excessive intake can worsen liver disease and should be avoided.
• Driving and machinery - UDCA does not impair cognition; no restrictions are necessary.
• Sun exposure - no known photosensitivity; standard sun protection is sufficient.

Dosing and Administration Guidelines

• Standard adult dose: 13-15 mg kg⁻¹ day⁻¹, divided into two or three doses. For a 70 kg adult, this equals roughly 900-1050 mg daily, typically taken as three 300 mg tablets.
• Typical regimen for PBC: 300 mg tablet taken three times a day with meals.
• Gallstone dissolution: same total daily dose, but treatment may continue for up to 6-24 months depending on stone response.
• Renal or hepatic impairment: no routine dose reduction, but clinicians may start at the lower end of the range and monitor closely.
• Missed dose: Take the missed tablet as soon as remembered unless it is near the time of the next scheduled dose; do not double the dose.
• Overdose: Symptoms may include severe diarrhoea, vomiting, and abdominal pain. Seek urgent medical care; there is no specific antidote.
• Discontinuation: Sudden cessation is generally safe, but in patients with advanced liver disease a gradual taper may be advised to avoid rebound cholestasis.

Monitoring and Follow-Up

• Liver-function tests (ALT, ALP, bilirubin): baseline, then every 3-6 months during the first year; frequency can be reduced if values remain stable.
• Serum cholesterol: monitor periodically, as UDCA can modestly increase HDL and lower LDL.
• Imaging for gallstones: ultrasound every 6-12 months to assess stone dissolution progress.
• Clinical assessment: evaluate symptoms of itching, fatigue, or jaundice at each follow-up visit.

Storage and Handling

• Store tablets at room temperature (15-25 °C) away from moisture and direct sunlight.
• Keep the container tightly closed.
• Do not use tablets after the printed expiry date.
• Dispose of unused medication according to local pharmacy guidelines; do not flush down the toilet.

Medication-Specific Glossary

Ursodeoxycholic Acid

A hydrophilic bile acid used to modify bile composition and protect liver cells.

Cholestasis

A condition where bile flow from the liver is reduced or blocked, leading to accumulation of bile acids in the bloodstream.

Cholelithiasis

The medical term for gallstone formation, most commonly composed of cholesterol.

Biliary Tract

The network of ducts that transport bile from the liver and gallbladder to the intestine.

Hepatoprotection

Strategies or agents that prevent damage to liver cells.

Medical Disclaimer

This article provides educational information about Actigall and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.